1. Academic Validation
  2. Discovery of a Negative Allosteric Modulator of GABAB Receptors

Discovery of a Negative Allosteric Modulator of GABAB Receptors

  • ACS Med Chem Lett. 2014 May 27;5(7):742-7. doi: 10.1021/ml500162z.
Lin-Hai Chen 1 Bing Sun 2 Yang Zhang 2 Tong-Jie Xu 2 Zhi-Xiong Xia 2 Jian-Feng Liu 2 Fa-Jun Nan 1
Affiliations

Affiliations

  • 1 National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai, China.
  • 2 Cellular Signaling Laboratory, Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology , Wuhan, Hubei, China.
Abstract

Initialized from the scaffold of CGP7930, an allosteric agonist of GABAB receptors, a series of noncompetitive antagonists were discovered. Among these compounds, compounds 3, 6, and 14 decreased agonist GABA-induced maximal effect of IP3 production in HEK293 cells overexpressing GABAB receptors and Gqi9 proteins without changing the EC50. Compounds 3, 6, and 14 not only inhibited agonist baclofen-induced ERK1/2 phosphorylation but also blocked CGP7930-induced ERK1/2 phosphorylation in HEK293 cells overexpressing GABAB receptors. The results suggested that compounds 3, 6, and 14 are negative allosteric modulators of GABAB receptors. The representative compound 14 decreased GABA-induced IP3 production with IC50 of 37.9 μM and had no effect on other GPCR Class C members such as mGluR1, mGluR2, and mGluR5. Finally, we showed that compound 14 did not bind to the orthosteric binding sites of GABAB receptors, demonstrating that compound 14 negatively modulated GABAB receptors activity as a negative allosteric modulator.

Keywords

CGP7930; GABAB receptors; negative allosteric modulator; α-keto acid.

Figures
Products